Viridian Therapeutics: Promising FcRn Inhibitor Developments and Strong Buy Recommendation
Leerink Partners analyst Thomas Smith reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report) on November 12 and set a ...